PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF inhibitors have revolutionized treatment of the disease and expanded the PsAtherapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative MOAs, such as the IL-12/23 inhibitor ustekinumab, the oral PDE-4 inhibitor apremilast, and the IL-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who have an inadequate response to TNF inhibitors.

Three biologics and three oral agents are in late-stage development for PsA and are expected to launch during the 2016-2026 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF inhibitor class.


Related Reports

Psoriatic Arthritis | Landscape & Forecast | Disease Landscape & Forecast

PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underd...

View Details

Psoriatic Arthritis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Market Outlook: Psoriatic arthritis (PsA) treatment typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics or targeted...

View Details

Psoriatic Arthritis | Unmet Need | Detailed, Expanded Analysis (US & EU)

MARKET OUTLOOK Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (

View Details

Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted ther...

View Details